Is PRRT (lutetium Lu 177) therapy available in Turkey?

Peptide receptor radionuclide therapy, or PRRT, uses lutetium Lu 177 dotatate — a nuclear-medicine treatment the National Cancer Institute describes for somatostatin-receptor-positive neuroendocrine tumors. It requires a Gallium-68 DOTATATE PET scan first to confirm your tumor takes up the tracer, and it is delivered only at centers with the right nuclear-medicine licensing and facilities. Whether it fits your case depends on your tumor type, grade and receptor status, so a free case review can flag what your reports already establish. You can verify a center's authorization yourself before you commit to anything.

Published 2026-07-21

← Back to all questions